Actelion Ltd. Chief Executive Officer Jean-Paul Clozel has staked the future of the company he founded on an experimental drug that analysts say has a 63 percent chance of success.
Drugmakers led by Novo Nordisk A/S and Merck & Co. are increasing sales efforts for their top- selling diabetes drugs to grab as much of the market as possible ahead of a wave of new therapies.
In trying to get sophisticated medicines to its neediest citizens, India is increasingly pitting its generic-pharmaceutical industry against international drugmakers, threatening their growth in emerging markets.
Novartis AG has a promising therapy for cancer. It’s just not sure how to get it to patients easily.
Alnylam Pharmaceuticals Inc. jumped the most in almost 18 months after Sanofi agreed to pay $700 million for access to rare-disease treatments and a 12 percent stake in the biotechnology company.